Jacobs Levy Equity Management’s Spero Therapeutics SPRO Stock Holding History

Jacobs Levy Equity Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-123,688	Closed	-$1.38M	–	1090
2020 Q3	$1.38M	Sell	123,688 -62,662	-34%	-$741K	0.01%	592
2020 Q2	$2.52M	Buy	186,350 +114,155	+158%	+$1.28M	0.03%	478
2020 Q1	$583K	Buy	72,195 +26,342	+57%	+$232K	0.01%	729
2019 Q4	$441K	Buy	45,853 +35,788	+356%	+$386K	﹤0.01%	800
2019 Q3	$107K	Buy	+10,065	New	+$106K	﹤0.01%	887
2019 Q2	–	Sell	-38,222	Closed	-$490K	–	1019
2019 Q1	$490K	Buy	38,222 +22,782	+148%	+$242K	0.01%	777
2018 Q4	$95K	Sell	15,440 -1,083	-7%	-$8.77K	﹤0.01%	943
2018 Q3	$174K	Sell	16,523 -17,155	-51%	-$199K	﹤0.01%	939
2018 Q2	$494K	Buy	+33,678	New	+$431K	0.01%	801

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Jacobs Levy Equity Management's SPRO Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of Spero Therapeutics (SPRO) in Q4 2020, closing a stake of 123,688 shares — an estimated $1.38M sold.

Jacobs Levy Equity Management first reported a position in SPRO in Q2 2018 and held it in 9 quarters. The position peaked at $2.52M in Q2 2020. 89 funds tracked by Wall St. Rank hold SPRO as of Q4 2020.

Jacobs Levy Equity Management reported no remaining Spero Therapeutics position as of Q4 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 123,688 Spero Therapeutics shares in Q4 2020, an estimated $1.38M.
Jacobs Levy Equity Management first reported a position in Spero Therapeutics in Q2 2018 and held it in 9 quarters.
Jacobs Levy Equity Management's Spero Therapeutics position peaked at $2.52M in Q2 2020.
89 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.